Mobile health applications in clinical practice: pearls, pitfalls, and key considerations

Annals of Allergy, Asthma & Immunology

August 2016 Vol. 117, Issue 2, p143–149

Overall Purpose:
Participants will be able to demonstrate increased knowledge of the clinical treatment of allergy/asthma/immunology and how new information can be applied to their own practices.

Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Planning Committee Members:

Victoria E. Cook, MD (Author)

Anne K. Ellis, MD (Author)

Kyla J. Hildebrand, MD, FRCPC, MScCH, (HPTE), (Author)

Jonathan A. Bernstein, MD (CME Subcommittee)

Guha Krishnaswamy, MD (CME Subcommittee)

John J. Oppenheimer, MD (CME Subcommittee, Associate Editor)

Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)

Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Describe mobile health applications and the potential benefits associated with use
  • Evaluate a mobile health application in regards to accessibility, content, and privacy 
Additional information
Disclosure: 

M.H. Grayson has received research grants from Children’s Research Institute/Children’s Hospital of Wisconsin, Merck, National Institutes of Health (NIH), and Polyphor. G.D. Marshall has received research grants from Amgen, AstraZeneca, Health Resources and Services Administration (HRSA) and National Institutes of Health (NIH). J.J. Oppenheimer has been a consultant/advisor for AstraZeneca, GlaxoSmithKline, Meda, Mylan, and Sunovion; has received research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis. J.A. Bernstein, G. Krishnaswamy, V.E. Cook, A.E. Ellis, K.J. Hildebrand, have no relevant financial relationships to disclose. Reviewers and Education/Editorial staff have no relevant financial relationships to disclose. Any unapproved/investigative uses of therapeutic agents/devices discussed are appropriately noted.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
08/01/2016
Course expires: 
07/31/2018
Cost:
$0.00

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Accreditation Period

Course opens: 
08/01/2016
Course expires: 
07/31/2018

Price

Cost:
$0.00
Please login or create an account to take this course.